EA202092084A1 - Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения - Google Patents

Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения

Info

Publication number
EA202092084A1
EA202092084A1 EA202092084A EA202092084A EA202092084A1 EA 202092084 A1 EA202092084 A1 EA 202092084A1 EA 202092084 A EA202092084 A EA 202092084A EA 202092084 A EA202092084 A EA 202092084A EA 202092084 A1 EA202092084 A1 EA 202092084A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
agonists
differentiation
growth
methods
Prior art date
Application number
EA202092084A
Other languages
English (en)
Inventor
Малгорзата Доната Гонсиарз
Виктор Х. Обунгу
Ричард Тодд Пикард
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202092084A1 publication Critical patent/EA202092084A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В данном документе предложены соединения, которые вызывают потерю массы тела и лечат диабет, дислипидемию, НАСГ и/или ожирение. Также предложены фармацевтические композиции, содержащие такие соединения, и варианты терапевтического применения таких соединений и композиций, при этом такие соединения действуют как агонисты GDF15 с продленным временем действия и другими полезными свойствами.
EA202092084A 2018-04-06 2019-03-29 Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения EA202092084A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06
PCT/US2019/024756 WO2019195091A1 (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Publications (1)

Publication Number Publication Date
EA202092084A1 true EA202092084A1 (ru) 2021-01-27

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092084A EA202092084A1 (ru) 2018-04-06 2019-03-29 Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения

Country Status (27)

Country Link
US (1) US11104711B2 (ru)
EP (1) EP3774860B1 (ru)
JP (1) JP7064618B2 (ru)
KR (1) KR102501922B1 (ru)
CN (1) CN112004821B (ru)
AR (1) AR115021A1 (ru)
AU (1) AU2019248535B2 (ru)
BR (1) BR112020017256A2 (ru)
CA (1) CA3096375C (ru)
CL (1) CL2020002564A1 (ru)
CO (1) CO2020012403A2 (ru)
CR (1) CR20200454A (ru)
DO (1) DOP2020000157A (ru)
EA (1) EA202092084A1 (ru)
EC (1) ECSP20062930A (ru)
ES (1) ES2937049T3 (ru)
IL (1) IL276980A (ru)
JO (1) JOP20200252B1 (ru)
MA (1) MA52228A (ru)
MX (1) MX2020010370A (ru)
PE (1) PE20212133A1 (ru)
PH (1) PH12020551656A1 (ru)
SG (1) SG11202009853VA (ru)
TW (1) TWI724392B (ru)
UA (1) UA127545C2 (ru)
WO (1) WO2019195091A1 (ru)
ZA (1) ZA202005385B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CA3226178A1 (en) 2021-08-24 2023-03-02 Jiangyu YAN Gdf15 fusion proteins and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP2571510B1 (en) * 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
CA2826142A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013364133B2 (en) * 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
SG11201600734YA (en) 2013-07-31 2016-02-26 Amgen Inc Stabilization of fc-containing polypeptides
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
EP3851445A1 (en) 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
MD20170020A2 (ru) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Композиции и методы, используемые для лечения нарушений метаболизма
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
CN115043945A (zh) * 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
CN107921089A (zh) 2015-04-02 2018-04-17 詹森生物科技公司 原毒素‑ii变体及使用方法
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
EP3413620A4 (en) 2016-02-29 2019-01-16 Huawei Technologies Co., Ltd. VIDEO OPTIMIZATION PROCEDURE, USER DEVICE UNIT AND NETWORK DEVICE UNIT
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
US20190309033A1 (en) 2019-10-10
EP3774860B1 (en) 2022-12-28
DOP2020000157A (es) 2020-09-15
CA3096375A1 (en) 2019-10-10
KR20200128091A (ko) 2020-11-11
UA127545C2 (uk) 2023-10-04
MX2020010370A (es) 2021-01-08
CA3096375C (en) 2023-09-12
PE20212133A1 (es) 2021-11-05
AU2019248535A1 (en) 2020-09-10
KR102501922B1 (ko) 2023-02-23
CO2020012403A2 (es) 2020-10-30
ZA202005385B (en) 2022-09-28
ECSP20062930A (es) 2020-11-30
JP2021517584A (ja) 2021-07-26
CL2020002564A1 (es) 2021-01-29
WO2019195091A1 (en) 2019-10-10
EP3774860A1 (en) 2021-02-17
CN112004821A (zh) 2020-11-27
MA52228A (fr) 2021-02-17
IL276980A (en) 2020-10-29
BR112020017256A2 (pt) 2020-12-22
SG11202009853VA (en) 2020-11-27
ES2937049T3 (es) 2023-03-23
CR20200454A (es) 2020-11-18
JOP20200252A1 (ar) 2020-10-04
TW201946661A (zh) 2019-12-16
TWI724392B (zh) 2021-04-11
JOP20200252B1 (ar) 2023-09-17
CN112004821B (zh) 2024-01-02
JP7064618B2 (ja) 2022-05-10
AU2019248535B2 (en) 2021-09-02
AR115021A1 (es) 2020-11-18
US11104711B2 (en) 2021-08-31
PH12020551656A1 (en) 2021-07-26

Similar Documents

Publication Publication Date Title
EA202092084A1 (ru) Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения
MX2019003790A (es) Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
EA202090448A1 (ru) Дигидрооксадиазиноны
EA202090414A1 (ru) Соединения и их применение
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
JOP20210224A1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل
EA201991898A1 (ru) Двойные ингибиторы magl и faah
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201991112A1 (ru) Композиции и способы, связанные с пиридиноилпиперидиновыми агонистами 5-ht1f
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
ZA202005083B (en) Solid forms of fasoracetam
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
EA202191294A1 (ru) Олигосахаридные композиции и способы их применения
MX2021000475A (es) Isoxazol como agonista del receptor fxr.
EA201991016A1 (ru) 2,4,5-трехзамещенные 1,2,4-триазолоны, применяемые в качестве ингибиторов дгодг